ATRS News and Press, Antares Pharma Inc. From 03/03/21

The following slide deck was published by Antares Pharma, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Antares Pharma, Inc. 2020 Q4 - Results - Earnings Call Presentation

Antares Pharma, Inc. (ATRS) Q4 2020 Earnings Conference Call March 2, 2021, 8:30 am ET Company Participants Tram Bui - VP, Corporate Communications & IR Bob Apple - President & CEO Fred Powell - EVP & CFO Pat Shea - SVP, Commercial Conference Call Participants Briana Warschun - Je...

Antares Pharma (ATRS): Q4 GAAP EPS of $0.30 beats by $0.26.Revenue of $44.1M (+16.5% Y/Y) beats by $1.79M.FY2021 guidance: revenue in the range of $175M-200M, which represents a 17% to 34% year-over-year growth rate vs consensus of $184.94M.Press Release For further details see: Antares...

Full-Year 2020 Revenue Increases 21% Year-Over-Year to $149.6 Million Full-Year 2020 Net Income Before Income Taxes of $9.9 Million, or $0.06 per Share Full-Year 2020 Net Income of $56.2 Million, including a Net Tax Benefit of $46.3 million EWING, N.J., March 02, 202...

EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present and host investor meetings at the Raymo...

EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year 2020 financial and operating results on Tuesday, March 2, 2021, before the ...

EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to participate and host investor meetings at the S...

Company has solid momentum behind it on the back of solid gains in the proprietary portfolio. Nocdurna is expected to drive sales higher in 2021. Multiple growth drivers should result in significantly higher prices in 2021. For further details see: Antares: Ready To Make...

Antares Pharma ([[ATRS]] +2.5%) expects revenue for FY 2021 to be in a range of $175-$200M, which assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic.The Co. also updated its guidance for FY 2020 and expects revenue to be in a range of $145-$150M fr...

EWING, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects revenue to be in a range of $175 to $200 million, which assumes no significant disru...